Search results
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 2 days agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
The Kansas City Star· 9 hours agoManufacturing is underway and doses of Moderna’s Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Benzinga· 6 hours agoOn Friday, Moderna Inc. MRNA announced that it has submitted an FDA application for review of its...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 11 hours agoEarlier in the year, one analyst called results from the cancer vaccine study "transformational."...
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
CNBC· 1 hour agoThe Food and Drug Administration on Friday expanded the approval of GSK's respiratory syncytial...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 6 hours ago"Simply put, Novavax's Covid vaccine results have shown better tolerability cross-trial than mRNA ...
mRESVIA’s FDA approval paves the way for mRNA vaccines across multiple indications
Clinical Trials Arena via Yahoo Finance· 1 day agovaccines have the advantage of being able to be quickly designed and produced, as mRNA molecules are...
New COVID-19 vaccine for fall should target JN.1 lineage, not variant, FDA panel
USA TODAY via Yahoo News· 2 days agoVaccine manufacturers Pfizer, Moderna and Novavax each told the panel they were prepared to make...
An mRNA Melanoma Vaccine Shows Promise
Time Magazine· 4 days agoModerna says the same mRNA technology that fueled its COVID-19 vaccine is proving effective in fighting melanoma. The company presented ...
Is Moderna Stock a Buy Now That It's a 2-Product Company? | The Motley Fool
The Motley Fool· 5 days agoThe shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna...